Lithuania has emerged as a global leader in biotechnology, with a sector that has grown over 170% in recent years and a national commitment to reach 5% of the country’s GDP by 2030. This thriving ecosystem provides the ideal, high-innovation landscape to accelerate your molecule from concept to commercial reality.
Our state-of-the-art 8,000 m² facility in Vilnius provides a fully integrated CDMO platform for the rapid development and cGMP manufacture of viral vectors and plasmid DNA. This purpose-built center features specialized biosafety suites designed for seamless scale-up from process development to commercial supply. Our capabilities encompass the full production lifecycle, including high-purity pDNA starting materials, upstream viral vector production, and sophisticated downstream purification. We ensure maximum process efficiency and rigorous regulatory compliance for next-generation genetic medicines.
Number of R&D laboratories
Gene Therapy facility size (m²)
pDNA fermentation range
Viral vector bioreactor range
BSL-3 manufacturing suites
